Previous 10 | Next 10 |
The FDA has released guidance on its standards for approving a COVID-19 vaccine, including a requirement that it must demonstrate that it is at least 50% more effective than placebo (a low bar compared to vaccines for other infectious diseases). More news on: AstraZeneca PLC, GlaxoSmithK...
Orgenesis (NASDAQ: ORGS ) added to the Russell 3000 Index, effective after the market open June 29 . More news on: Orgenesis Inc., Soleno Therapeutics, Inc., Cidara Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics f...
The silver lining in the persistence of COVID-19 infections, at least for some investors, is the bullish outlook for companies developing vaccines and/or therapies for the respiratory infection. More news on: Vir Biotechnology, Inc., Dynavax Technologies Corporation, Novavax, Inc., Healthc...
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics f...
Overview of Becton Dickinson’s businesses Becton Dickinson (BDX) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physi...
SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for ra...
Arcturus Therapeutics ' (NASDAQ: ARCT) stock saw deep losses on May 27, in part because of spillover from news about patients in Moderna 's (NASDAQ: MRNA) COVID-19 vaccine trial experiencing adverse reactions. Because both companies are working on COVID-19 vaccines, bad news ...
Gainers: Hertz Global (NYSE: HTZ ) +104% . More news on: Hertz Global Holdings, Inc., Euroseas Ltd., Mersana Therapeutics, Inc., Stocks on the move, , Read more ...
NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings I...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...